Scholars@Duke
Journal cover image

Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.

Publication ,  Journal Article
Aminsharifi, A; Polascik, TJ
Published in: Eur Urol
August 2018
Published version (DOI) Link to item

Duke Scholars

Thomas James Polascik
Author Thomas James Polascik Urology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Urol

DOI

10.1016/j.eururo.2018.01.022

EISSN

1873-7560

Publication Date

August 2018

Volume

74

Issue

2

Start / End Page

234 / 235

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Prostatic Neoplasms
  • Prognosis
  • Prevalence
  • Male
  • Humans
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aminsharifi, A., & Polascik, T. J. (2018). Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy. Eur Urol, 74(2), 234–235. https://doi.org/10.1016/j.eururo.2018.01.022
Aminsharifi, Alireza, and Thomas J. Polascik. “Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.” Eur Urol 74, no. 2 (August 2018): 234–35. https://doi.org/10.1016/j.eururo.2018.01.022.
Aminsharifi, Alireza, and Thomas J. Polascik. “Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.” Eur Urol, vol. 74, no. 2, Aug. 2018, pp. 234–35. Pubmed, doi:10.1016/j.eururo.2018.01.022.
Journal cover image

Published In

Eur Urol

DOI

10.1016/j.eururo.2018.01.022

EISSN

1873-7560

Publication Date

August 2018

Volume

74

Issue

2

Start / End Page

234 / 235

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Prostatic Neoplasms
  • Prognosis
  • Prevalence
  • Male
  • Humans
  • 3202 Clinical sciences
  • 1103 Clinical Sciences